Pursuant to Regulation 30 and Schedule III part A of SEBI Listing Regulations, Investor Presentation on audited Standalone and Consolidated Financial Results for the quarter and financial ....
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech reported a challenging FY26 with revenue declining 12% YoY to Rs 1,054.9 Cr and PAT falling 30% to Rs 259.2 Cr. Q4FY26 saw even sharper declines with revenue at Rs 326.1 Cr (-24% YoY) and PAT at Rs 88.5 Cr (-37% YoY). Margins contracted significantly with EBITDA margin down 736 bps to 34.8% for FY26 and PAT margin at 24.6%. The company attributed declines to delayed procurement decisions, US tariff uncertainty, customer shift to staggered purchasing, EU regulatory delays, and Middle East geopolitical headwinds. Management remains optimistic about FY27 citing strong order pipeline and customer acquisition momentum. Key positives include new injectable facility commercialization, US commercial presence via Stellon Biotech, entry into cell and gene therapy via Cellimune Biotech, and multiple global regulatory inspections successfully completed.
The significant margin contraction and revenue decline in FY26 indicate near-term earnings pressure. However, management's emphasis on strong order pipeline and new growth platforms suggests potential recovery in FY27. Shareholders should monitor execution of US commercialization and injectable facility ramp-up.